Skip to main navigation Skip to search Skip to main content

Colonic oncostatin M expression evaluated by immunohistochemistry and infliximab therapy outcome in corticosteroid-refractory acute severe ulcerative colitis

  • Jim O’Connell
  • , Jayne Doherty
  • , Amy Buckley
  • , David Cormican
  • , Cara Dunne
  • , Karen Hartery
  • , John Larkin
  • , Finbar MacCarthy
  • , Paul McCormick
  • , Susan McKiernan
  • , Brian Mehigan
  • , Cian Muldoon
  • , Ciara Ryan
  • , Jacintha O’Sullivan
  • , David Kevans

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Ulcerative colitis (UC) is a chronic relapsing remitting inflammatory disease of the colon. The lifetime risk of presentation with acute severe ulcerative colitis (ASUC) is 15%.1 Patients with ASUC receive first line therapy with intravenous corticosteroids, however, approximately 30% have corticosteroid-refractory disease.2,3 In this situation, rescue medical therapy options include the anti-tumor necrosis factor (TNF) monoclonal antibody infliximab (IFX) or the calcineurin inhibitor ciclosporin.2 A significant proportion of patients fail to respond to IFX therapy with reported colectomy rates at 1 year of 35%.4 Biomarkers which identify patients with corticosteroid-refractory ASUC, with a reduced likelihood of IFX response, would significantly advance clinical care for these patients.

Original languageEnglish
Pages (from-to)381-385
JournalIntestinal Research
Volume20
Issue number3
Early online date31 Dec 2022
DOIs
Publication statusPublished - 31 Dec 2022

Fingerprint

Dive into the research topics of 'Colonic oncostatin M expression evaluated by immunohistochemistry and infliximab therapy outcome in corticosteroid-refractory acute severe ulcerative colitis'. Together they form a unique fingerprint.

Cite this